Mucolipidosis type II/III (GNPTAB-related)

Mucolipidosis type II (ML II) and mucolipidosis type III (ML III) are conditions that cause individuals to have difficulty transporting certain digestive enzymes into part of their cells called the lysosome. This causes a toxic build-up of molecules inside the lysosomes.

Individuals with ML II are small at birth, with poor muscle tone, a weak cry, bone abnormalities, and developmental delay. Unfortunately, children with ML II usually do not survive past early childhood.

Individuals with ML III have a milder experience of ML than those with ML II. Differences are usually noticed by age 3 with slow growth and short stature. Children develop progressive bone and heart disease and experience respiratory difficulties. Symptoms of MLIII can be managed and children often live into adulthood, but their life span tends to be shortened.

Quick facts about mucolipidosis type II/III (GNPTAB-related)
Genes: GNPTAB
Inheritance: Autosomal Recessive
Relevant resources for mucolipidosis type II/III (GNPTAB-related)

A quick genetics rundown

As humans we have about 23,000 genes. These genes are like tiny instruction manuals that influence our health, growth and development. We inherit half of our genes from our biological mum and the other half from our biological dad. These genes are lined up on structures called chromosomes. Most of us have 23 pairs of chromosomes. The first 22 pairs are called autosomes and for the most part - these are the same among men and women. The 23rd pair determine our sex - two X chromosomes for a female and one X and one Y chromosome for males.

Learn more about genetics

How is mucolipidosis type II/III (GNPTAB-related) inherited?

mucolipidosis type II/III (GNPTAB-related) is known as an autosomal recessive condition. For autosomal recessive conditions, if a person has a variation in one copy of their gene, they are a carrier. This means that they are healthy because they also have a working copy of the gene. But, they can still pass their non-working copy to their child.

If the other parent also happens to be a carrier of the same gene, there is a 25% (1 in 4) chance that they both pass this gene variation on to their child — and as such, have a child affected by the disease.

If both parents are carriers of mucolipidosis type II/III (GNPTAB-related), there’s a one in four chance that their children could develop symptoms.
Learn more about carrier screening

What is carrier screening?

Carrier testing is like a checkup for your genes. It tests to see if you carry a gene variation that could cause a serious genetic disease in your child. Eugene offers an inclusive genetic carrier screening panel that includes mucolipidosis type II/III (GNPTAB-related), but there's a total 301 conditions that can be tested.

Eugene’s carrier test is a clinical grade test that can be done from the comfort of your own home — it’s just a saliva test. You're also paired with a genetic counsellor who provides mindful support and guidance every step of the way.

Learn more about carrier screening

Should parents screen for mucolipidosis type II/III (GNPTAB-related) before or early in pregnancy?

The biggest benefit of screening for mucolipidosis type II/III (GNPTAB-related) is that it can help future parents understand their reproductive risk so they can be ready and empowered to make more informed decisions. If neither partner are carriers, it provides reassurance and peace of mind that the risk of having a child with a genetic disease is low.

Since 90% of children that have a recessive genetic disease like mucolipidosis type II/III (GNPTAB-related) had no previous family history of it, it often feels completely out of the blue for the parents. Getting screened is a way to know this risk in advance, which can help familes manage or even prevent the disease in the first place.

Wondering if this test is right for you?

Take a two minute quiz to find out.